Organophosphate ester flame retardants have antiandrogenic potential and affect other endocrine related endpoints

Anna Kjerstine Rosenmai1, Sofia Boeg Winge1, Morlin Möller1

  • 1Division of Diet Disease Prevention and Toxicology, National Food Institute, Technical University of Denmark, 2800 Kgs, Lyngby, Denmark.

Chemosphere
|August 28, 2020
PubMed

Insights

Organophosphate ester flame retardants (OPFRs) pose endocrine disruption risks. This study screened eleven OPFRs using in vitro and in silico methods, revealing significant impacts on androgen receptor and aryl hydrocarbon receptor activity, necessitating further human risk assessment.

Area of Science:

  • Environmental Chemistry
  • Toxicology
  • Molecular Biology

Background:

  • Organophosphate ester flame retardants (OPFRs) are widely used, leading to human exposure across all life stages.
  • While in vivo endocrine effects are known, molecular-level data and the role of chemical substructures are less understood.

Purpose of the Study:

  • To screen eleven OPFRs for endocrine-disrupting potential using in vitro and in silico assays.
  • To investigate the influence of chemical substructures on OPFR endocrine activity.

Main Methods:

  • In vitro assays: androgen receptor (AR), aryl hydrocarbon receptor (AhR), Nrf2 activity, steroidogenesis, and transthyretin (TTR) binding.
  • In silico models: estrogen, thyroid, and CYP3A4 induction.
  • Selection of eleven OPFRs based on limited endocrine data or varied chemical structures.

Main Results:

  • Ten OPFRs impacted AR and AhR activity; seven affected TTR binding; five altered 17β-estradiol levels.
  • Several OPFRs showed potent effects (IC50 < 10 μM), including TPHP, CDP, TMPP, TIPPP, and EHDPP for AR antagonism.
  • Arylated OPFRs were predicted to interact with the estrogen receptor, while chlorinated OPFRs showed minimal TTR binding effects.

Conclusions:

  • OPFRs exhibit significant endocrine-disrupting potential at the molecular level.
  • Chemical substructures like arylation and molecular size influence OPFR activity.
  • Further research is crucial for comprehensive human risk assessment of OPFRs.

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.4K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
805
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.7K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.4K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.7K
Properties of Organometallic Compounds01:23

Properties of Organometallic Compounds

Organometallic compounds are compounds that contain a carbon–metal bond. Carbon belongs to an organyl group like alkyl, aryl, allyl, or benzyl groups. The metal can be from Group I or Group II of the periodic table, a transition metal, or a semimetal.
1.5K